Pendopharm Receives Honours Thanks to Cingal®

The excellence and commitment of Pendopharm have been recognized globally as Distributor of the Year for its innovative product Cingal® by its business partner, Anika Therapeutics, Inc.

Cingal® is the only single combination product for the relief of pain caused by osteoarthritis of the knee available in Canada since 2016. This injectable treatment solidifies our commitment to the well-being of Canadians suffering from musculoskeletal pain.

“Pendopharm is proud to have received the following honours: Osteoarthritis Pain Management 2022: Regional Distributor of the Year, Americas and the prize 2022 Worldwide Cingal® Excellence Award, Engagement & Growth.

This recognition demonstrates our commitment to patients and healthcare communities to provide innovative products that address unmet medical needs,” Jad Isber, Vice President, and General Manager at Pendopharm.

The team would like to thank the medical community for constantly pushing us to stay ahead of the curve and go above and beyond for the well-being of patients.

ABOUT PENDOPHARM

Established in 2010, Pendopharm is the branded specialty division of Pharmascience Inc. We are a leading Canadian specialty pharmaceutical company dedicated to developing, in-licensing and commercializing innovative products. Pendopharm is committed to providing patients and the healthcare community with innovative medicines that address unmet medical needs.  Our portfolio of branded products is focused on four core therapeutic areas, where we have proven expertise: Gastroenterology, Sports Medicine & Orthopedics, Neurology and Cardiology.  In addition, we have a portfolio of established medicines, offering more than 40 specialty products across multiple therapeutic areas.